Reprieve Cardiovascular

Executive Summary

Reprieve Cardiovascular is a privately held medical device company based in Boston, founded in 2018. The company is developing the Reprieve System, an intelligent decongestion management (IDM) solution designed to safely accelerate fluid removal in patients with acute decompensated heart failure (ADHF). By providing real-time data and personalized control over diuretic therapy, the system aims to address a major cause of heart failure hospitalizations and improve patient outcomes. The company has not yet commercialized a product and operates in the early-stage medtech space, with a focus on regulatory approval and clinical validation.

Upcoming Catalysts (preview)

• Q1 2027FDA 510(k) Clearance or PMA Submission for Reprieve System40% success
• Q3 2026Pivotal Clinical Trial Results for Decongestion Management50% success
• Q2 2026Series A or B Financing Round to Support Commercialization70% success